

Cover Story
ClinicalRegulatory NewsTrials & Tribulations
In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL).
Cancer Policy
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Early-onset colorectal cancer is behaving like a new, biologically distinct disease, researchers note
One woman’s pregnancy shows how this distinction matters - Cancer patients with Medicare Advantage have access to fewer providers than Medicare patients, cross-sectional study finds
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data in ACS guideline support greater use of noninvasive tests to ease system strain, save lives - More than 50 million Americans remain unscreened for colon cancer
New guidelines offer another option - A new diagnostic lens—and a lasting scientific legacy

















